Martin “Pharma Bro” Shkreli’s testimony – or lack thereof – at a House Oversight Committee hearing (or lack thereof) justifiably angered many people. The infamous former hedge fund CEO turned pharma executive raised the price of a generic anti-parasitic drug – Daraprim – by 5,000 percent last year simply because he could. Overnight, he became the embodiment of a pharmaceutical industry routinely accused of putting profit-seeking before patient health.
